Literature DB >> 10768976

Role of lipopolysaccharide phase variation in susceptibility of Haemophilus influenzae to bactericidal immunoglobulin M antibodies in rabbit sera.

A L Erwin1, Y A Brewah, D A Couchenour, P R Barren, S J Burke, G H Choi, R Lathigra, M S Hanson, J N Weiser.   

Abstract

The effect of phase variation of lipopolysaccharide (LPS) structure on the susceptibility of Haemophilus influenzae to complement-dependent killing by normal human sera and normal rat sera has been described previously. The phase-variable structure phosphorylcholine (ChoP) confers susceptibility to human serum, since ChoP on the bacterial cell surface binds to serum C-reactive protein and activates complement. In contrast, expression of galalpha1,4gal, a second phase-variable epitope that is also found on human glycoconjugates, confers resistance to human serum. We studied the role of phase variation of these structures in the susceptibilities of H. influenzae KW20 (Rd) and a clinical isolate of nontypeable H. influenzae to killing by rabbit sera, which often possess naturally acquired complement-dependent bactericidal activity for unencapsulated H. influenzae. Expression of ChoP increased the resistance of strain KW20 to killing by bactericidal rabbit sera. In contrast, the serum resistance of a clinical isolate, H233, was unaffected by ChoP expression but was reduced by galalpha1,4gal expression. The rabbit sera with bactericidal activity (but not the nonbactericidal sera) all contained immunoglobulin M (IgM) antibodies able to bind to the surface of H. influenzae bacteria, as detected by flow cytometry, and contained IgM antibodies to LPS purified from strain KW20. Preincubation of sera with LPS reduced their bactericidal activity. Bactericidal activity was recovered quantitatively in an IgM-enriched fraction of sera. It is concluded that naturally occurring bactericidal activity for unencapsulated H. influenzae is largely due to IgM antibodies directed against phase-variable structures of the LPS.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10768976      PMCID: PMC97491          DOI: 10.1128/IAI.68.5.2804-2807.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  20 in total

1.  Isolation and characterization of mutants of Haemophilus influenzae deficient in an adenosine 5'-triphosphate-dependent deoxyribonuclease activity.

Authors:  K W Wilcox; H O Smith
Journal:  J Bacteriol       Date:  1975-05       Impact factor: 3.490

2.  Molecular analysis of a complex locus from Haemophilus influenzae involved in phase-variable lipopolysaccharide biosynthesis.

Authors:  D J Maskell; M J Szabo; P D Butler; A E Williams; E R Moxon
Journal:  Mol Microbiol       Date:  1991-05       Impact factor: 3.501

3.  Structural analysis of the lipopolysaccharide oligosaccharide epitopes expressed by a capsule-deficient strain of Haemophilus influenzae Rd.

Authors:  A Risberg; H Masoud; A Martin; J C Richards; E R Moxon; E K Schweda
Journal:  Eur J Biochem       Date:  1999-04

4.  Identification and characterization of SirA, an iron-regulated protein from Staphylococcus aureus.

Authors:  J H Heinrichs; L E Gatlin; C Kunsch; G H Choi; M S Hanson
Journal:  J Bacteriol       Date:  1999-03       Impact factor: 3.490

5.  The Protective or Curative Element in Type B H. influenzae Rabbit Serum.

Authors:  H E Alexander; M Heidelberger; G Leidy
Journal:  Yale J Biol Med       Date:  1944-05

6.  Whole-genome random sequencing and assembly of Haemophilus influenzae Rd.

Authors:  R D Fleischmann; M D Adams; O White; R A Clayton; E F Kirkness; A R Kerlavage; C J Bult; J F Tomb; B A Dougherty; J M Merrick
Journal:  Science       Date:  1995-07-28       Impact factor: 47.728

7.  Outer membrane protein composition in disease isolates of Haemophilus influenzae: pathogenic and epidemiological implications.

Authors:  M R Loeb; D H Smith
Journal:  Infect Immun       Date:  1980-12       Impact factor: 3.441

8.  Protection of infant rats from Haemophilus influenzae type b infection by antiserum to purified outer membrane protein a.

Authors:  M R Loeb
Journal:  Infect Immun       Date:  1987-11       Impact factor: 3.441

9.  The role of a repetitive DNA motif (5'-CAAT-3') in the variable expression of the Haemophilus influenzae lipopolysaccharide epitope alpha Gal(1-4)beta Gal.

Authors:  N J High; M E Deadman; E R Moxon
Journal:  Mol Microbiol       Date:  1993-09       Impact factor: 3.501

10.  Phosphorylcholine on the lipopolysaccharide of Haemophilus influenzae contributes to persistence in the respiratory tract and sensitivity to serum killing mediated by C-reactive protein.

Authors:  J N Weiser; N Pan; K L McGowan; D Musher; A Martin; J Richards
Journal:  J Exp Med       Date:  1998-02-16       Impact factor: 14.307

View more
  5 in total

1.  Antibodies specific for the high-molecular-weight adhesion proteins of nontypeable Haemophilus influenzae are opsonophagocytic for both homologous and heterologous strains.

Authors:  Linda E Winter; Stephen J Barenkamp
Journal:  Clin Vaccine Immunol       Date:  2006-10-04

Review 2.  Microbial modulation of host immunity with the small molecule phosphorylcholine.

Authors:  Sarah E Clark; Jeffrey N Weiser
Journal:  Infect Immun       Date:  2012-12-10       Impact factor: 3.441

3.  Phosphorylcholine expression by nontypeable Haemophilus influenzae correlates with maturation of biofilm communities in vitro and in vivo.

Authors:  Wenzhou Hong; Bing Pang; Shayla West-Barnette; W Edward Swords
Journal:  J Bacteriol       Date:  2007-06-15       Impact factor: 3.490

4.  Human antibodies specific for the high-molecular-weight adhesion proteins of nontypeable Haemophilus influenzae mediate opsonophagocytic activity.

Authors:  Linda E Winter; Stephen J Barenkamp
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

5.  Molecular basis of increased serum resistance among pulmonary isolates of non-typeable Haemophilus influenzae.

Authors:  Shigeki Nakamura; Mikhail Shchepetov; Ankur B Dalia; Sarah E Clark; Timothy F Murphy; Sanjay Sethi; Janet R Gilsdorf; Arnold L Smith; Jeffery N Weiser
Journal:  PLoS Pathog       Date:  2011-01-06       Impact factor: 6.823

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.